Nanion Corporate Blog

 

10.09.2019: Press Release - Launch of the FLEXcyte 96

Launch of the FLEXcyte 96 – pushing the boundaries of cardiac safety screening.

Nanion Technologies is proud to announce the launch of the FLEXcyte 96 technology for cardiac contraction force measurements. Improving patient safety and reducing animal tests while saving time and money by replacing unnecessary in vivo experiments is the aim of this novel assay technology.

The FLEXcyte 96 has been developed in cooperation with innoVitro GmbH. Read the full press release here

Back to Overview

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.